Tenax Therapeutics (TENX) to Release Earnings on Thursday

Tenax Therapeutics (NASDAQ:TENX) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Tenax Therapeutics to post earnings of ($0.51) per share for the quarter.

Tenax Therapeutics Stock Up 2.9 %

Tenax Therapeutics stock opened at $6.43 on Thursday. The stock’s 50 day simple moving average is $6.44 and its two-hundred day simple moving average is $5.30. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a report on Thursday, March 13th. They set a “sell” rating for the company. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a report on Monday, March 10th. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.